Literature DB >> 18714312

Preventing growth of brain tumors by creating a zone of resistance.

Casey A Maguire1, Dimphna H Meijer, Stanley G LeRoy, Laryssa A Tierney, Marike L D Broekman, Fabricio F Costa, Xandra O Breakefield, Anat Stemmer-Rachamimov, Miguel Sena-Esteves.   

Abstract

Glioblastoma multiforme (GBM) is a devastating form of brain cancer for which there is no effective treatment. Here, we report a novel approach to brain tumor therapy through genetic modification of normal brain cells to block tumor growth and effect tumor regression. Previous studies have focused on the use of vector-based gene therapy for GBM by direct intratumoral injection with expression of therapeutic proteins by tumor cells themselves. However, as antitumor proteins are generally lethal to tumor cells, the therapeutic reservoir is rapidly depleted, allowing escape of residual tumor cells. Moreover, it has been difficult to achieve consistent transduction of these highly heterogeneous tumors. In our studies, we found that transduction of normal cells in the brain with an adeno-associated virus (AAV) vector encoding interferon-beta (IFN-beta) was sufficient to completely prevent tumor growth in orthotopic xenograft models of GBM, even in the contralateral hemisphere. In addition, complete eradication of established tumors was achieved through expression of IFN-beta by neurons using a neuronal-restricted promoter. To our knowledge this is the first direct demonstration of the efficacy of targeting gene delivery exclusively to normal brain cells for brain tumor therapy.

Entities:  

Mesh:

Year:  2008        PMID: 18714312      PMCID: PMC2863297          DOI: 10.1038/mt.2008.168

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  48 in total

1.  A herpes simplex virus type 1 mutant with gamma 34.5 and LAT deletions effectively oncolyses human U87 glioblastomas in nude mice.

Authors:  Ken Samoto; Moneeb Ehtesham; Guey-Chuen Perng; Kazuhiro Hashizume; Steven L Wechsler; Anthony B Nesburn; Keith L Black; John S Yu
Journal:  Neurosurgery       Date:  2002-03       Impact factor: 4.654

Review 2.  Potential of gene therapy for brain tumors.

Authors:  P Y Lam; X O Breakefield
Journal:  Hum Mol Genet       Date:  2001-04       Impact factor: 6.150

3.  Efficacy of adenoviral p53 delivery with SCH58500 in the intracranial 9l and RG2 models.

Authors:  Geoffrey Bowers; Ju He; Karl Schulz; Gregory Olivarria; Dan Maneval; Jeffrey J Olson
Journal:  Front Biosci       Date:  2003-05-01

4.  Distribution of AAV-TK following intracranial convection-enhanced delivery into rats.

Authors:  J Cunningham; Y Oiwa; D Nagy; G Podsakoff; P Colosi; K S Bankiewicz
Journal:  Cell Transplant       Date:  2000 Sep-Oct       Impact factor: 4.064

5.  Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis.

Authors:  Jonathan I Izawa; Paul Sweeney; Paul Perrotte; Daniel Kedar; Zhongyun Dong; Joel W Slaton; Takashi Karashima; Keji Inoue; William F Benedict; Colin P N Dinney
Journal:  Clin Cancer Res       Date:  2002-04       Impact factor: 12.531

6.  Highly efficient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors.

Authors:  Wei Jun Wang; Chien-Kuo Tai; Noriyuki Kasahara; Thomas C Chen
Journal:  Hum Gene Ther       Date:  2003-01-20       Impact factor: 5.695

7.  Adeno-associated virus vector-mediated transduction in the cat brain.

Authors:  Charles H Vite; Marco A Passini; Mark E Haskins; John H Wolfe
Journal:  Gene Ther       Date:  2003-10       Impact factor: 5.250

8.  Direct evidence that IFN-beta functions as a tumor-suppressor protein.

Authors:  Campbell Kaynor; Mei Xin; John Wakefield; James Barsoum; Xiao-Qiang Qin
Journal:  J Interferon Cytokine Res       Date:  2002-11       Impact factor: 2.607

9.  Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo.

Authors:  Khalid Shah; Yi Tang; Xandra Breakefield; Ralph Weissleder
Journal:  Oncogene       Date:  2003-10-09       Impact factor: 9.867

10.  Antitumor effect of an adeno-associated virus vector containing the human interferon-beta gene on experimental intracranial human glioma.

Authors:  Jun Yoshida; Masaaki Mizuno; Norimoto Nakahara; Peter Colosi
Journal:  Jpn J Cancer Res       Date:  2002-02
View more
  25 in total

1.  Microvesicle-associated AAV vector as a novel gene delivery system.

Authors:  Casey A Maguire; Leonora Balaj; Sarada Sivaraman; Matheus H W Crommentuijn; Maria Ericsson; Lucia Mincheva-Nilsson; Vladimir Baranov; Davide Gianni; Bakhos A Tannous; Miguel Sena-Esteves; Xandra O Breakefield; Johan Skog
Journal:  Mol Ther       Date:  2012-02-07       Impact factor: 11.454

2.  Heparin blocks transfer of extracellular vesicles between donor and recipient cells.

Authors:  Nadia A Atai; Leonora Balaj; Henk van Veen; Xandra O Breakefield; Peter A Jarzyna; Cornelis J F Van Noorden; Johan Skog; Casey A Maguire
Journal:  J Neurooncol       Date:  2013-09-04       Impact factor: 4.130

Review 3.  Genetic therapy for the nervous system.

Authors:  William J Bowers; Xandra O Breakefield; Miguel Sena-Esteves
Journal:  Hum Mol Genet       Date:  2011-03-23       Impact factor: 6.150

Review 4.  Gene therapy for the nervous system: challenges and new strategies.

Authors:  Casey A Maguire; Servio H Ramirez; Steven F Merkel; Miguel Sena-Esteves; Xandra O Breakefield
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

5.  Intrathecal Adeno-Associated Viral Vector-Mediated Gene Delivery for Adrenomyeloneuropathy.

Authors:  Yi Gong; Anna Berenson; Fiza Laheji; Guangping Gao; Dan Wang; Carrie Ng; Adrienn Volak; Rene Kok; Vasileios Kreouzis; Inge M Dijkstra; Stephan Kemp; Casey A Maguire; Florian Eichler
Journal:  Hum Gene Ther       Date:  2018-12-18       Impact factor: 5.695

6.  Systemic AAV9-IFNβ gene delivery treats highly invasive glioblastoma.

Authors:  Dwijit GuhaSarkar; Qin Su; Guangping Gao; Miguel Sena-Esteves
Journal:  Neuro Oncol       Date:  2016-05-18       Impact factor: 12.300

7.  Optimal in silico target gene deletion through nonlinear programming for genetic engineering.

Authors:  Chung-Chien Hong; Mingzhou Song
Journal:  PLoS One       Date:  2010-02-24       Impact factor: 3.240

8.  Directed evolution of adeno-associated virus for glioma cell transduction.

Authors:  Casey A Maguire; Davide Gianni; Dimphna H Meijer; Lev A Shaket; Hiroaki Wakimoto; Samuel D Rabkin; Guangping Gao; Miguel Sena-Esteves
Journal:  J Neurooncol       Date:  2009-07-19       Impact factor: 4.130

9.  Virus vector-mediated genetic modification of brain tumor stromal cells after intravenous delivery.

Authors:  Adrienn Volak; Stanley G LeRoy; Jeya Shree Natasan; David J Park; Pike See Cheah; Andreas Maus; Zachary Fitzpatrick; Eloise Hudry; Kelsey Pinkham; Sheetal Gandhi; Bradley T Hyman; Dakai Mu; Dwijit GuhaSarkar; Anat O Stemmer-Rachamimov; Miguel Sena-Esteves; Christian E Badr; Casey A Maguire
Journal:  J Neurooncol       Date:  2018-05-16       Impact factor: 4.130

Review 10.  Adeno-associated virus (AAV) vectors in cancer gene therapy.

Authors:  Jorge L Santiago-Ortiz; David V Schaffer
Journal:  J Control Release       Date:  2016-01-12       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.